Efficacy Study of Levocarnitine Adjuvant Therapy for Complications of Heart Failure
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v4i4.1421
Abstract
The objective is to investigate the role of standard treatment combined with Levocarnitine (LC) in improving clinical outcomes in patients with complications of heart failure. The authors collected and organized data from 700 patients with complications of heart failure admitted to our cardiology department from January 2015 to February 2020. The patients were divided into a control group and an LC group, with 350 cases in each group. The control group received standard treatment, while the LC group received standard treatment combined with LC. The authors compared left ventricular ejection fraction (LVEF) and brain natriuretic peptide (BNP) levels between the two groups. Results: The LVEF level in the LC group was higher than that in the control group after treatment, with P<0.05. The BNP levels were similar between the two groups after treatment, with P>0.05. In the LC group, the LVEF level in patients with heart failure and diabetes was higher than that in the control group, and the BNP level was lower than that in the control group, with P<0.05. In patients with heart failure and atrial fibrillation in the LC group, the LVEF level was higher than that in the control group (P<0.05), and the BNP levels were similar between the two groups (P>0.05) after treatment. In patients with heart failure and dilated cardiomyopathy in the LC group, the LVEF level was higher than that in the control group, and the BNP level was lower than that in the control group, with P<0.05. Conclusion: LC combined with standard treatment can more significantly improve LVEF and BNP levels in patients with complications of heart failure, especially in the subgroup of heart failure with diabetes.
Keywords
Levocarnitine, heart failure complications, efficacy, left ventricular ejection fraction, brain natriuretic peptide
Full Text
PDF - Viewed/Downloaded: 3 TimesReferences
[1] Zhao J, Zhao S. Efficacy Analysis of CRRT Combined with L-Carnitine in the Treatment of Chronic Renal Failure Complicated with Acute Heart Failure[J]. Chinese Journal of Modern Medicine, 2021, 31(10): 15-19.
[2] Hu S. Current Status and Future Considerations of Ventricular Assist Device Treatment for Heart Failure[J]. Chinese Journal of Heart Failure and Cardiomyopathy (in Chinese and English), 2022, 6(2): 77-79.
[3] Yang S, Tang X, Yang X, et al. Effect of L-Carnitine Assisted Mechanical Ventilation on Inflammatory Response and Cardiac Function in Children with Heart Failure[J]. Journal of Practical Cardiovascular and Cerebrovascular Disease, 2022, 30(7): 96-99.
[4] Feng L, Liang W, Zhao J, et al. Effect of Valsartan Combined with L-Carnitine on the Cardiorenal Function of Patients with Chronic Renal Failure Undergoing Hemodialysis Complicated with Heart Failure[J]. Hainan Medical Journal, 2022, 33(9): 1122-1125.
[5] Zhang K, Wu B. Effect of L-Carnitine Combined with Telmisartan on Heart Function, Inflammatory Factors, and D-Dimer Levels in Patients with Congestive Heart Failure[J]. Journal of Cardiovascular Rehabilitation Medicine, 2021, 30(5): 578-582.
[6] Ji D, Zhang Y. Effect of L-Carnitine Combined with Irbesartan on Renal Function, Oxidative Stress, and Inflammatory Response in Patients with Diabetic Nephropathy[J]. Medical Clinical Research, 2022, 39(5): 644-647.
[7] Xu H, Huang Y. Effect of Perindopril Combined with L-Carnitine on Exercise Tolerance in Patients with Heart Failure[J]. Chinese Journal of Multi-Organ Diseases in the Elderly, 2021, 20(5): 349-354.
[8] Liu D, Hao WY, Su Q, et al. Effect of Irbesartan Combined with L-Carnitine on Serum Toll-like Receptor-4, Retinol-binding Protein, and Prealbumin in Patients with End-stage Diabetic Nephropathy[J]. Journal of Chinese PLA Medical Society, 2021, 33(2): 47-50.
[2] Hu S. Current Status and Future Considerations of Ventricular Assist Device Treatment for Heart Failure[J]. Chinese Journal of Heart Failure and Cardiomyopathy (in Chinese and English), 2022, 6(2): 77-79.
[3] Yang S, Tang X, Yang X, et al. Effect of L-Carnitine Assisted Mechanical Ventilation on Inflammatory Response and Cardiac Function in Children with Heart Failure[J]. Journal of Practical Cardiovascular and Cerebrovascular Disease, 2022, 30(7): 96-99.
[4] Feng L, Liang W, Zhao J, et al. Effect of Valsartan Combined with L-Carnitine on the Cardiorenal Function of Patients with Chronic Renal Failure Undergoing Hemodialysis Complicated with Heart Failure[J]. Hainan Medical Journal, 2022, 33(9): 1122-1125.
[5] Zhang K, Wu B. Effect of L-Carnitine Combined with Telmisartan on Heart Function, Inflammatory Factors, and D-Dimer Levels in Patients with Congestive Heart Failure[J]. Journal of Cardiovascular Rehabilitation Medicine, 2021, 30(5): 578-582.
[6] Ji D, Zhang Y. Effect of L-Carnitine Combined with Irbesartan on Renal Function, Oxidative Stress, and Inflammatory Response in Patients with Diabetic Nephropathy[J]. Medical Clinical Research, 2022, 39(5): 644-647.
[7] Xu H, Huang Y. Effect of Perindopril Combined with L-Carnitine on Exercise Tolerance in Patients with Heart Failure[J]. Chinese Journal of Multi-Organ Diseases in the Elderly, 2021, 20(5): 349-354.
[8] Liu D, Hao WY, Su Q, et al. Effect of Irbesartan Combined with L-Carnitine on Serum Toll-like Receptor-4, Retinol-binding Protein, and Prealbumin in Patients with End-stage Diabetic Nephropathy[J]. Journal of Chinese PLA Medical Society, 2021, 33(2): 47-50.
Copyright © 2023 Kaili Du, Qixiao Jiang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License